Phase 2 Trial of the DPP-1 Inhibitor Brensocatib in Bronchiectasis

The causal role of neutrophil serine proteases in the pathogenesis of bronchiectasis was studied with brensocatib, an inhibitor of protease activation. Brensocatib therapy resulted in a longer time to the first bronchiectasis exacerbation than placebo.

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The New England journal of medicine 2020-11, Vol.383 (22), p.2127-2137
Hauptverfasser: Chalmers, James D, Haworth, Charles S, Metersky, Mark L, Loebinger, Michael R, Blasi, Francesco, Sibila, Oriol, O’Donnell, Anne E, Sullivan, Eugene J, Mange, Kevin C, Fernandez, Carlos, Zou, Jun, Daley, Charles L
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:The causal role of neutrophil serine proteases in the pathogenesis of bronchiectasis was studied with brensocatib, an inhibitor of protease activation. Brensocatib therapy resulted in a longer time to the first bronchiectasis exacerbation than placebo.
ISSN:0028-4793
1533-4406
DOI:10.1056/NEJMoa2021713